#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Maintenance Therapy After Oxaliplatin Discontinuation Based on Panitumumab

Panitumumab is an approved therapy for metastatic colorectal cancer without RAS oncogene mutation (wtRAS mCRC) and has been evaluated for 1st-line treatment through randomized phase II (PEAK) and III (PRIME) studies. A retrospective analysis of these studies assessed the efficacy and safety of panitumumab as the basis for therapy in these patients after discontinuation/termination of oxaliplatin.
Source: Colorectal Cancer 20. 2. 2020

News Should We Test for Alpha-1-Antitrypsin in All COPD Patients?

Approximately 1–2% of patients with chronic obstructive pulmonary disease (COPD) have an alpha-1-antitrypsin (AAT) deficiency. This is an underdiagnosed genetic disorder that leads to rapid progression of COPD, although it is initially amenable to therapeutic intervention. Therefore, it is necessary to improve early detection of affected individuals. General practitioners can play a crucial role in this process.
Source: Deficiency of Alpha-1-Antitrypsin 10. 2. 2020

News New Era in Migraine Therapy

Migraine is the most common type of primary headache. It affects about 10% of the world population. Recurring migraine attacks significantly reduce quality of life. Therefore, research in pharmacotherapy in recent years has logically focused on preventing attacks. The result is the latest possibility of biological treatment for migraines using monoclonal antibodies against CGRP receptors.
Source: Migraine 4. 5. 2020

News MS, NMOSD and COVID-19: What Did a Year of Pandemic in Czechia Mean for Our Patients and Which Risk Factors Were Confirmed?

What is the incidence and course of COVID-19 in patients with multiple sclerosis (MS) and diseases from the broader spectrum of neuromyelitis optica (NMOSD) in Czechia? And which risk factors pertain to this specific population? Data from the ReMuS registry, summarized in an article by Czech authors recently published in the journal Multiple Sclerosis and Related Disorders, revealed this and more. We offer a unique insight into the issue of COVID-19 in these patients in our conditions.
Source: Multiple Sclerosis 28. 7. 2021

News Non-Steroidal Anti-Inflammatory Drugs in the Treatment of Ankylosing Spondylitis: Network Meta-Analysis

A literature review and network meta-analysis of randomized controlled trials published in the journal Experimental and Therapeutic Medicine demonstrates the high efficacy and good tolerability of 6 non-steroidal anti-inflammatory drugs (NSAIDs) including etoricoxib, celecoxib, meloxicam, diclofenac, naproxen, and ß-D-mannuronic acid in the treatment of ankylosing spondylitis (AS).
Source: Updates in Pain Treatment 30. 3. 2023

News Prediabetes through the lens of current data and findings − and why hurry with intervention

Type 2 diabetes mellitus (DM2) is one of the most common causes of premature morbidity and mortality worldwide. The most serious impact on the health of the organism is mainly due to the macrovascular complications of this disease. However, their occurrence was often recorded before the diagnosis of DM2 was confirmed. Prediabetes itself thus represents a condition associated with the risk of developing cardiovascular (CV) complications with all their prognostic implications for patients.
Source: Diabetes 27. 7. 2022

News Micronutrients in Parenteral Nutrition in Adult Patients – Current Issues and Consensus

Micronutrients are a key nutritional component, and this is also true for patients whose condition requires the administration of parenteral nutrition. An article published last year in the Journal of Parenteral and Enteral Nutrition summarizes the expert literature on this topic as well as current guidelines and addresses 14 clinically most relevant questions related to the importance, administration, and monitoring of micronutrients.
Source: Parenteral Nutrition 23. 11. 2020

News Extended Thromboprophylaxis with Enoxaparin After Bariatric Surgery

A recent retrospective study involving 312 patients after bariatric surgery indicated that extended thromboprophylaxis might be an appropriate approach for preventing postoperative venous thromboembolism in these patients. In this study, the authors administered enoxaparin at a dose of 40 mg subcutaneously twice daily for 10-14 days in the majority of operated patients without an increased risk of bleeding.
Source: Thromboprophylaxis 29. 4. 2021

News What is the Impact of Bisoprolol on Plasma Concentrations of Dabigatran

Many patients on anticoagulant therapy with dabigatran also use the beta-blocker bisoprolol. The Slovak prospective observational study was based on the assumption that bisoprolol, as a significant inhibitor of P-glycoprotein, may interact with dabigatran and focused on examining the effect of this beta-blocker on plasma concentrations of dabigatran.
Source: Cardiovascular Continuum 16. 9. 2022

News Can alpha-1-antitrypsin deficiency affect severity and higher mortality in COVID-19 patients?

Alpha-1-antitrypsin (AAT) deficiency is commonly found in the European population. The most cases are recorded in countries with the highest COVID-19 mortality rates. Are there direct correlations?
Source: Deficiency of Alpha-1-Antitrypsin 12. 4. 2021

News Quality of Life of Patients on Adjuvant Treatment for HER2-Positive Breast Cancer

The KATHERINE clinical trial demonstrated that adjuvant therapy with trastuzumab emtansine compared to trastuzumab significantly improves invasive disease-free survival in patients with HER2-positive early breast cancer and residual invasive disease after prior treatment. A post hoc analysis of this study was published in the journal Cancer, focusing on patient-reported outcomes related to quality of life during and after treatment.
Source: Breast Carcinoma 28. 5. 2020

News Biosimilar Bevacizumab in Patients with Non-Small Cell Lung Cancer

Biosimilar drugs are essentially analogous to generics for biological medicines. The patent protection for the original bevacizumab product will expire in the European Union in 2022. Consequently, several companies have already embarked on developing a biosimilar molecule.
Source: Oncological Treatment 15. 9. 2021

News Prophylaxis with Enoxaparin After Total Knee or Hip Replacement

Venous thromboembolic disease is a significant cause of complications in surgical patients during and after hospitalization. The authors of a recently published Portuguese observational study evaluated the incidence of complications with prophylaxis using low-molecular-weight heparin (LMWH) enoxaparin in a population after hip or knee joint replacement.
Source: Thromboprophylaxis 28. 11. 2023

News Finger on the Pulse of the Times with Automated Peritoneal Dialysis and Remote Patient Monitoring

The method of peritoneal dialysis brings many advantages to patients with chronic kidney disease and significantly eases their lives. Peritoneal dialysis saves time for both the patients themselves and the attending healthcare personnel. Modern medicine now offers an innovative tool that can remotely monitor the patient's condition, with the possibility of adjusting the treatment regimen.
Source: Chronic Kidney Disease 29. 9. 2020

News Position of Enoxaparin and DOACs in Extended Prevention of VTE After Surgeries for Gynecological Malignancies

The prophylaxis of venous thromboembolism is a crucial part of postoperative management in oncological diseases, including gynecological malignancies. A newly published survey study conducted in Australia and New Zealand focused precisely on these. The authors were interested in different types of postoperative prophylactic regimens and the potential use of direct oral anticoagulants (DOACs) in them.
Source: Thromboprophylaxis 3. 1. 2024

News Clinical Results of the Pinnacle Acetabular System: Data from the UK Joint Replacement Registry

The Pinnacle Acetabular System has been available on the market for nearly two decades. Since then, it has been implanted in numerous healthcare facilities worldwide. Clinical outcomes of the acetabular system were evaluated by analyzing data from the National Joint Replacement Registry of England, Wales, Northern Ireland, and the Isle of Man.
Source: Large Joints 22. 4. 2020

News Low-Molecular-Weight Heparin as Adjuvant Therapy in Small-Cell Lung Cancer − Results of the RASTEN Study

Several studies and meta-analyses in the past have pointed to a possible positive effect of low-molecular-weight heparins (LMWH) in the treatment of cancer. The RASTEN study therefore focused on the potential effect of enoxaparin in patients with small-cell lung cancer (SCLC).
Source: Thromboprophylaxis 18. 2. 2020

News Does Dosage Frequency Matter for Adherence to Anticholinergic Treatment in Patients with COPD?

A study by Spanish authors compared the adherence of patients with chronic obstructive pulmonary disease (COPD) to anticholinergic treatment administered once every 12 hours and once every 24 hours.
Source: Treatment of Asthma and COPD 15. 5. 2020

News Transthyretin Amyloidosis in Patients with Carpal Tunnel Syndrome

Carpal tunnel syndrome is considered a warning sign for cardiac amyloidosis. Amyloid deposits are often found in the tenosynovial material removed during surgery. However, the prevalence of concomitant cardiomyopathy is not yet fully understood. Japanese researchers from Kumamoto University recently focused on the relationship between carpal tunnel syndrome and cardiac amyloidosis in their newly published prospective study.
Source: Amyloidosis 10. 11. 2023

News Efficacy of Empagliflozin in HFpEF Patients – Comparison of Subpopulations with Preserved and Mid-Range LV EF

A sub-analysis of the EMPEROR-Preserved clinical trial examined the effects and safety of empagliflozin in patients with heart failure with a left ventricular ejection fraction (LV EF) > 40%. What insights does it provide regarding the impact on cardiovascular (CV) mortality or the need for hospitalization for heart failure (HHF) concerning left ventricular function?
Source: Heart Failure 24. 8. 2023

News Importance of Home Parenteral Therapy: ESPEN Recommendations from 2020

Home parenteral therapy currently plays a crucial role in the treatment and prevention of malnutrition in specific patient groups. The European Society for Clinical Nutrition and Metabolism (ESPEN) published updated guidelines for home parenteral therapy in 2020, based on current evidence and expert recommendations.
Source: Parenteral Nutrition 7. 6. 2021

Journal articles Fatal meningococcal sepsis caused by Neisseria meningitidis serogroup W

Author of the article: L. Krbková, M. Fedora, J. Pavelka, P. Křížová, K. Labská, Z. Vacková Source: Česko-slovenská pediatrie | 5/2017 9. 10. 2017

News Pegylated Liposomal Irinotecan + 5-FU/LV in the Treatment of mPDAC in Czech Clinical Practice – Results from the VILP Registry

At last year's annual congress of the European Society for Medical Oncology (ESMO) and this year's 15th PragueONCO, results from the Czech VILP registry were presented. This registry collected data on patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with pegylated liposomal irinotecan (nal-IRI) in combination with 5-fluorouracil (5-FU) and leucovorin (LV). The efficacy and safety of nal-IRI + 5-FU/LV in patients with mPDAC after failure or intolerance to gemcitabine-based chemotherapy, as found in the randomized controlled study NAPOLI-1, are thus confirmed in real clinical practice in the Czech Republic.
Source: Treatment of Gastrointestinal Carcinomas 25. 3. 2024

News Overall Survival in Patients with Metastatic CRC During 1st-Line Anti-EGFR Treatment Depending on the Presence or Absence of Hypomagnesemia

Hypomagnesemia is one of the side effects of monoclonal antibody therapy against the epidermal growth factor receptor (EGFR). The study presented below examined overall survival in patients with metastatic primarily unresectable colorectal cancer (CRC) treated with anti-EGFR therapy depending on the presence or absence of hypomagnesemia.
Source: Colorectal Cancer 3. 10. 2022

News 6 Years Follow-Up of Patients with Breast Cancer in the APHINITY Study

The primary analysis of results from the APHINITY clinical trial supported the combined anti-HER2 treatment with trastuzumab and pertuzumab in combination with chemotherapy in patients with early HER2-positive breast cancer. At the end of last year, efficacy and safety results of this treatment after more than 6 years of follow-up were presented.
Source: Breast Carcinoma 17. 4. 2020

1 25 26 27 28 29 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#